News articles about Obalon Therapeutics (NASDAQ:OBLN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Obalon Therapeutics earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 48.0616106421668 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of brokerages have issued reports on OBLN. Zacks Investment Research upgraded Obalon Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research note on Thursday. UBS Group cut their price target on Obalon Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, November 10th. BTIG Research cut their price target on Obalon Therapeutics from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Finally, Northland Securities reiterated a “sell” rating and issued a $4.00 price target on shares of Obalon Therapeutics in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $12.10.

Shares of Obalon Therapeutics (OBLN) opened at $7.90 on Friday. Obalon Therapeutics has a 12 month low of $6.53 and a 12 month high of $13.18. The company has a quick ratio of 8.65, a current ratio of 8.78 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $137.79, a price-to-earnings ratio of -3.97 and a beta of -3.50.

Obalon Therapeutics (NASDAQ:OBLN) last issued its quarterly earnings results on Friday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.12). Obalon Therapeutics had a negative return on equity of 59.77% and a negative net margin of 459.54%. The business had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $2.95 million. equities analysts expect that Obalon Therapeutics will post -1.98 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Obalon Therapeutics (OBLN) Share Price” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-obalon-therapeutics-obln-share-price/1806881.html.

Obalon Therapeutics Company Profile

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Insider Buying and Selling by Quarter for Obalon Therapeutics (NASDAQ:OBLN)

Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.